Julie Rosenthal, MD
Cardiovascular Disease · Phoenix, AZNPI 1326282302
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,981 of the $22,268 with a category attached, or 76.3%. Novo Nordisk AS accounts for 68.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $15,687 and has fallen 98.0% since, to $307 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $767.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$15K
- Pfizer$5K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$432
- Edwards Lifesciences$287
- Abbott$245
- Medtronic$205
- plus $558 from 5 others
Across 29 payments — averaging $10,027 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$254K
- Ionis Pharmaceuticals, Inc.$37K
What the payments were for
- Consulting fees$16,98176%
- Travel & lodging$2,93713%
- Food & beverage$2,26210%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 5 | $15,317 |
| Pfizer | 5 | $5,224 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $432 |
| Edwards Lifesciences | 2 | $287 |
| Abbott | 5 | $245 |
| Medtronic | 2 | $205 |
| AstraZeneca | 1 | $167 |
| Bridgebio Pharma, Inc. | 1 | $146 |
| Abiomed | 1 | $122 |
| Alnylam Pharmaceuticals Inc. | 1 | $76 |
| Akcea Therapeutics, Inc. | 1 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$5,216
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$287
- LifeVest$226
- Attruby$146
- HeartWare HVAD$129
- CARDIOMEMS$103
- CardioMEMS HF System$102
How this compares
$22,268 in reported general payments places this provider in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 408 | $10,132,286 |
| VyndaqelTafamidis Meglumine | 70 | $1,793,572 |
| EntrestoSacubitril/Valsartan | 132 | $162,853 |
| EliquisApixaban | 112 | $135,391 |
| JardianceEmpagliflozin | 109 | $121,059 |
| FarxigaDapagliflozin Propanediol | 92 | $84,954 |
| XareltoRivaroxaban | 52 | $46,596 |
| Sirolimus | 23 | $10,187 |
| Mycophenolate Mofetil | 33 | $8,991 |
| DapagliflozinDapagliflozin Propanediol | 16 | $8,260 |
| Eplerenone | 63 | $5,797 |
| Tacrolimus | 36 | $3,881 |
| Torsemide | 141 | $2,767 |
| Mycophenolic AcidMycophenolate Sodium | 15 | $2,342 |
| Potassium Chloride | 54 | $2,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $5,224 | $12,061,248590 claims |
| AstraZenecaFarxiga | $167 | $84,95492 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Phoenix
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Tabitha MoePhoenix$182K
- Jesse SethiPhoenix$150K
- Robert ScottPhoenix$106K
- Kethes WaramPhoenix$66K
- Ayman JamalPhoenix$42K
- Sarika DesaiPhoenix$41K
- Suzanne SorofPhoenix$29K
- Namit RohantPhoenix$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.